Weill Cornell Medicine at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Weill Cornell Medicine brings 1 presentation to ASH 2026 in New Orleans. Its program spans transplant complications, acute myeloid leukemia and blood clots. It also gives an update on managing intermediate-risk pulmonary embolism, and covers endothelial injury and complement in TA-TMA after allogeneic transplant.
| Organization | ASH 2026 Attendance |
|---|---|
Weill Cornell Medicine New York, NY | |
Cornell University's medical school and research enterprise in New York City, partnered with NewYork-Presbyterian Hospital. | Symposium Fri Dec 11 7:00pm–10:00pm Cases and Conversations™: Endothelial Injury, Complement, and TA-TMA After Allogeneic Stem Cell Transplant Picking graft sources such as expanded cord blood, and treating transplant-associated thrombotic microangiopathy with a newly approved complement inhibitor. Symposium Fri Dec 11 11:00am–2:00pm Medical Crossfire®: Precision Decisions in AML – Experts Debating Frontline Therapy, Targeted Agents, and Sequencing Across Care Frontline therapy, targeted drugs, and treatment sequencing in acute myeloid leukemia, framed around real questions from community oncologists. Talk Update on the Management of Intermediate Risk Pulmonary Embolism Classifying and treating intermediate-risk pulmonary embolism, including when early intervention is worth its risks, under updated multi-society guidelines. |
Instantly find 20 buyers from Weill Cornell Medicine
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction